2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance
This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia
This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …
good for the greatest number of people with familial hypercholesterolaemia (FH) across …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the …
BA Ference, HN Ginsberg, I Graham… - European heart …, 2017 - academic.oup.com
Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs)
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel
Although awareness of familial hypercholesterolemia (FH) is increasing, this common,
potentially fatal, treatable condition remains underdiagnosed. Despite FH being a genetic …
potentially fatal, treatable condition remains underdiagnosed. Despite FH being a genetic …
[HTML][HTML] 20-year follow-up of statins in children with familial hypercholesterolemia
IK Luirink, A Wiegman, DM Kusters… - … England Journal of …, 2019 - Mass Medical Soc
Background Familial hypercholesterolemia is characterized by severely elevated low-
density lipoprotein (LDL) cholesterol levels and premature cardiovascular disease. The …
density lipoprotein (LDL) cholesterol levels and premature cardiovascular disease. The …
[PDF][PDF] 2016 European Guidelines on cardiovascular disease prevention in clinical practice
MF Piepoli, AW Hoes, S Agewall… - Polish Heart …, 2016 - journals.viamedica.pl
2.3. 9. Wnioski................................................ 838 2.4. Inne markery ryzyka.......................................
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias
AL Catapano, I Graham, G De Backer… - Polish Heart …, 2016 - journals.viamedica.pl
5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
Prevention of atherosclerosis from childhood
O Raitakari, K Pahkala, CG Magnussen - Nature Reviews Cardiology, 2022 - nature.com
Cardiovascular diseases caused by atherosclerosis do not typically manifest before middle
age; however, the disease process begins early in life. Preclinical atherosclerosis can be …
age; however, the disease process begins early in life. Preclinical atherosclerosis can be …